Close Menu

Illumina TruSight Tumor 170

Nov 07, 2016

Illumina has launched TruSight Tumor 170, a next-generation sequencing-based panel that targets SNVs, gene amplifications, gene fusions, and splice variants found in 170 cancer-related genes. The panel analyzes both DNA and RNA and requires 40 nanograms of input from formalin-fixed paraffin-embedded samples. The panel will begin shipping in the first quarter 2017 for research use only. 

More Like This

May 22, 2020

Genedata Imagence 2.0

Genedata has released Genedata Imagence 2.0, the latest version of its enterprise software high-content screening image analysis. The new version offers full end-to-end automation, reducing the time spent on image analysis by an order of magnitude. It enables the analysis of complex phenotypic assay formats without extensive expert input, and the transfer of gained knowledge to new experimental setups. It has also been further optimized for use of distributed computing resources. In particular, the parallelization of image analysis steps results in massive time and cost savings, the company said. Similar to other components of the Genedata Biopharma Platform, the new software can be deployed using on-demand cloud computing service providers like Amazon Web Services.

May 20, 2020

10x Genomics Targeted Gene Expression Solution

10x Genomics has launched its Targeted Gene Expression Solution for single-cell sequencing.

The firm is offering kits for predesigned gene panels relevant to cancer, immunology, neuroscience, and drug targeting applications, with the option for customization.

May 19, 2020

Aalto Bio Reagents Recombinant SARS-CoV-2 Spike Proteins

Dublin-based Aalto Bio Reagents has released a range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers, and researchers globally. The S protein is the main antigenic component that is responsible for inducing host immune responses and neutralizing antibodies, making it the principal focus of therapeutic and vaccine design for COVID-19. When used solely or in combination with Aalto's new insect-derived nucleocapsid protein (N), the company's S1-S2 chimeric glycoprotein has demonstrated excellent reactivity in ELISA for the detection of IgA, IgG and IgM antibodies against SARS-CoV-2, the company said.

May 19, 2020

Thermo Fisher Scientific Invitrogen RiboMinus Bacteria 2.0 Transcriptome Isolation Kit

Thermo Fisher Scientific has released the Invitrogen RiboMinus Bacteria 2.0 Transcriptome Isolation Kit for the probe-based depletion of ribosomal RNA from bacteria. The kit, which can be automated on Thermo Fisher KingFisher instruments, uses a novel magnetic bead-based purification technology to selectively deplete rRNA transcripts from total RNA. It now includes 5S targets and more than 100 probe designs to yield improved rRNA depletion and can be utilized with RNA from a wide variety of species.

May 19, 2020

Oxford Immunotec T-Spot Discovery SARS-CoV-2 RUO Kit

Oxford Immunotec Global has launched the T-Spot Discovery SARS-CoV-2 test kit for research use only. The kit builds on its experience with tuberculosis diagnosis and the assessment of the immune response to cytomegalovirus infections in transplant patients. Using the company's established T-Spot technology, the kit interrogates the immune system's T-cell response and will enable research into the measurement of the strength of that response to SARS-CoV-2, Oxford Immunotec said.

May 14, 2020

EnGenome eVai Variant Interpretation/Genomenon Mastermind Genomic Search Engine

Genomenon's Mastermind Genomic Search Engine has been integrated into the eVai Variant Interpretation platform from EnGenome, Genomenon said. eVai users can now preview the number of published articles related to their search and easily link out to view the evidence in Mastermind. By combining artificial intelligence with ACMG-AMP guidelines, eVai classifies and prioritizes every genomic variant for pathogenicity, suggesting all possible related genetic diagnoses. Mastermind has indexed more than 7.5 million full-text articles and 1.5 million supplemental data sets, and covers more than 6.1 million variants found in the medical literature.

May 14, 2020

Biocept Target Selector BRAF RUO Kits

Biocept has launched a Target Selector research-use-only molecular assay for the detection of BRAF mutations in both formalin-fixed, paraffin-embedded samples and blood samples. The kits use the company's Switch-Blocker technology to enrich the specimen for mutations of interest, resulting in ultra-high assay sensitivity and specificity. Biocept said that in general, its Target Selector kits can detect mutations of interest in circulating tumor DNA at a level of one mutant copy in 10,000 wildtype molecules. The assays can be used with a variety of analytical platforms including qPCR, Sanger sequencing, next generation sequencing, microarrays, and mass spectrometry. The new BRAF kit complements the company's previously launched EGFR mutation-detection assay.

May 13, 2020

ZeptoMetrix NATSARS(CoV-2) Quality Controls

ZeptoMetrix has launched its ready-to-use NATSARS(CoV-2) molecular quality controls, including its NATtrol SARS-CoV-2 Positive Control and NATtrol SARS-CoV-2 Negative Control. The firm said the tools are formulated with purified intact viral particles chemically modified to render them non-infectious and refrigerator stable. ZeptoMetrix said the products will provide laboratories external run controls to help establish the reliability of COVID-19 testing.

May 12, 2020

Beckman Coulter Life Sciences RNAdvance Viral XP

Beckman Coulter Life Sciences announced the launch of its new RNA extraction kit, RNAdvance Viral XP. The kit is validated for use in infectious disease and real-time PCR virus research and is intended for use in high-throughput settings to extract viral RNA from swab samples, the firm said. After it has been extracted, the RNA is used in qRT-PCR kits to determine whether the virus is present. Danaher subsidiary Beckman Coulter worked with next-generation sequencing company iRepertoire to develop the kit's method, which iRepertoire then independently validated. 

May 12, 2020

Roche KAPA Target Enrichment Portfolio

Roche launched its new KAPA Target Enrichment product portfolio, which includes both exome and custom target enrichment solutions for sequencing. The KAPA HyperExome is a whole-exome research panel with improved performance compared to the existing SeqCap portfolio that targets the GRCh38/hg38 geome assembly. Roche's HyperDesign tool allows for the creation of custom target enrichment designs using the KAPA HyperChoice probes. The target enrichment portfolio will increase sequencing efficiency, the company said. The new probes will replace the SeqCap product portfolio, which is expected to be discontinued in the first quarter of 2022. 

May 11, 2020

LGC SARS-CoV-2 Verification Panel and Reference Materials; Charité ValuPanel Assay Reagents

LGC Seracare has launched new versions of its AccuPlex Verification Panel and Reference Material Kit for SARS-CoV-2 testing. The previous versions contained negative control material targeting the human RNase P gene and positive control material for the viral ORF1a, RdRp, E, and N gene consensus sequences targeted in the US Centers for Disease Control and Prevention and World Health Organization assays. They have now been expanded to include the S gene region of the virus. 

In addition, LGC Biosearch Technologies has launched new assays in its ValuPanel line. The Charité 2019-nCoV BHQ and BBQ-650 ValuPanel Reagent sets use oligonucleotide sequencedesigned by the German Center for Infection Research (DZIF) at Charité. The firm also now offers US CDC 2019-nCoV BHQ ValuPanel Reagents sets, and continues to offer the 2019-nCoV CDC-qualified Probe and Primer Kits for SARS-CoV-2.

May 08, 2020

Samplix Xdrop Services

Danish company Samplix has launched a comprehensive service program granting laboratories access to its Xdrop technology for complex genomic research including gap closing, sequencing of repeat elements, viral insertion site detection, revealing unintended CRISPR edits, and more. Xdrop enriches genomic regions longer than 100 kb from as little as 1 ng of human genomic DNA and with single-molecule resolution. It requires knowledge of only a short sequence within or flanking the target region for efficient target selection. Following targeted selection, multiple displacement amplification is applied to single DNA molecules compartmentalized in droplets. This ensures unbiased amplification of large DNA fragments that are representative of the target variation in the original sample. The output is ready for any short-read or long-read sequencing platform, the company said.

May 07, 2020

Sartorius Incucyte SX5

Sartorius has launched its Incucyte SX5 Live-Cell Analysis system. The firm said that the tool applies novel optics, a new line of paired reagents, and purpose-built software to help researchers draw greater insights from live cell experiments. The Incucyte system has five different fluorescence channels, of which Sartorius said up to three can be used at once. Because the optical module uses long wavelength near infrared fluorescence, researchers will be able to image sensitive cell types on the platform up to months without requiring to be removed from the incubator. 

May 06, 2020

Thermo Fisher Scientific Ion AmpliSeq SARS-CoV-2 Research Panel

Thermo Fisher Scientific has launched the Ion AmpliSeq SARS-CoV-2 Research Panel. It consists of two pools with amplicons 125 to 275 base pairs in length that cover more than 99 percent of the viral genome, and requires as little as 1 ng of total RNA input. The panel runs on the Ion GeneStudio S5 sequencer and was recently optimized to also run on the Ion Torrent Genexus system.

May 05, 2020

Saama, Indx.AI COVID-19 Command Center

Clinical analytics firm Saama Technologies and multiomics data integrator Indx.AI have launched COVID-19 Command Center, a cloud-based platform to help life sciences companies accelerate R&D on potential therapies and vaccines for COVID-19. The product is meant to allow trial sponsors working on in-house clinical development to manage studies with the same technology offered by the recently established EndPandemic National Data Consortium, which Saama launched and of which Indx.AI is a founding member.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.